The past decade experienced a lot of shuffling in the Rheumatoid arthritis market. The journey started with the approvals of disease-modifying anti-rheumatic drugs (DMARDs). Several conventional DMARDs constituting methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, biologics with initial entrants being etanercept and leflunomide in 1998, followed by infliximab, adalimumab, certolizumab pegol, and golimumab entered the market. B-cell targeting therapies have also been investigated in recent years, with rituximab being the only one approved by the US FDA in 2006. Most recently, tocilizumab, a monoclonal antibody directed against the IL-6 receptor also got...
